Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING Phase 2

Probiotic Use for Recovery Enhancement From Long COVID-19

NCT06643299 · View on ClinicalTrials.gov ↗

Study Summary

The goal of this clinical trial is to learn if probiotics can improve symptoms and quality of life in participants with Long COVID.

Interventions

  • OTHER Placebo
  • DRUG Probiotic Agent

Study Locations (1)

Illinois

  • Rush University Medical Center — Chicago

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2025-05-13
Est. Completion 2026-07
Phase Phase 2

Sponsor

Rush University Medical Center

168 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06643299

The ClinicalTrials.gov registry entry for NCT06643299 describes a study currently listed as active not recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rush University Medical Center, which has 168 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Post-Acute COVID-19 Syndrome appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06643299 reports 1 study location spanning 1 distinct geographic area — top geographies include Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06643299 about?

NCT06643299 is a clinical study titled "Probiotic Use for Recovery Enhancement From Long COVID-19". The goal of this clinical trial is to learn if probiotics can improve symptoms and quality of life in participants with Long COVID.

What is the current status of trial NCT06643299?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2025-05-13. Estimated completion is 2026-07.

What conditions does trial NCT06643299 study?

This clinical trial studies the following conditions: Post-Acute COVID-19 Syndrome. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06643299?

The interventions under investigation include: Placebo (OTHER), Probiotic Agent (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06643299?

This trial is sponsored by Rush University Medical Center, which has 168 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06643299 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial